Human hCG Visual ELISA Kit

The extragalactic cosmic gamma-ray background (CGB) is an interesting channel to look for signatures of dark matter annihilation. In particular, besides the imprint in the energy spectrum, peculiar anisotropy patterns are expected compared to the case of a pure astrophysical origin of the CGB. We take into account the uncertainties in the dark matter clustering properties on subgalactic scales, deriving two possible anisotropy scenarios. A clear dark matter angular signature is achieved when the annihilation signal receives only a moderate contribution from subgalactic clumps and/or cuspy haloes. Experimentally, if galactic foreground systematics are efficiently kept under control, the angular differences are detectable with the forthcoming GLAST observatory, provided that the annihilation signal contributes to the CGB for a fraction greater than or similar to 10-20%. If, instead, subgalactic structures have a more prominent role, the astrophysical and dark matter anisotropies become degenerate, correspondingly diluting the dark matter signature. As complementary observables we also introduce the cross correlation between surveys of galaxies and the CGB and the cross correlation between different energy bands of the CGB, and we find that they provide a further sensitive tool to detect the dark matter angular signatures.

Epigenetic marks such as cytosine methylation are important determinants of cellular and whole-body phenotypes. However, the extent of, and reasons for inter-individual differences in cytosine methylation, and their association with phenotypic variation are poorly characterised. Here we present the first genome-wide study of cytosine methylation at single-nucleotide resolution in an animal model of human disease. We used whole-genome bisulfite sequencing in the spontaneously hypertensive rat (SHR), a model of cardiovascular disease, and the Brown Norway (BN) control strain, to define the genetic architecture of cytosine methylation in the mammalian heart and to test for association between methylation and pathophysiological phenotypes. Analysis of 10.6 million CpG dinucleotides identified 77,088 CpGs that were differentially methylated between the strains. In F1 hybrids we found 38,152 CpGs showing allele-specific methylation and 145 regions with parent-of-origin effects on methylation. Cis-linkage explained almost 60% of inter-strain variation in methylation at a subset of loci tested for linkage in a panel of recombinant inbred (RI) strains. Methylation analysis in isolated cardiomyocytes showed that in the majority of cases methylation differences in cardiomyocytes and noncardiomyocytes were strain-dependent, confirming a strong genetic component for cytosine methylation. We observed preferential nucleotide usage associated with increased and decreased methylation that is remarkably conserved across species, suggesting a common mechanism for germline control of inter-individual variation in CpG methylation. In the RI strain panel, we found significant correlation of CpG methylation and levels of serum chromogranin B (CgB), a proposed biomarker of heart failure, which is evidence for a link between germline DNA sequence variation, CpG methylation differences and pathophysiological phenotypes in the SHR strain. Together, these results will stimulate further investigation of the molecular basis of locally regulated variation in CpG methylation and provide a starting point for understanding the relationship between the genetic control of CpG methylation and disease phenotypes.